Seaside research sees possible autism treatment

Wed, 09/19/2012 - 12:00am
Mass High Tech: The Journal of New England Technology


Seaside Therapeutics Inc. in Cambridge Wednesday published its latest research results for its disease-modifying drug candidate STX209 that shows promise as a treatment for fragile X syndrome and autism, the most prevalent form of intellectual disability.


In two papers published online today in Science Translational Medicine, STX209, also called arbaclofen, shows potential for modifying the disease known as fragile X syndrome (FXS), the most common known genetic cause for autism, resulting in impaired social function, cognition and speech, as well as attention deficits and low functional independence. To date, the only treatment for FXS and autism has been anti-psychotic drugs which calm the patient but do not address the underlying disease nor the social and communication problems patients experience with FXS.





Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.